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Borna disease is an immune-mediated neurologic syndrome (31) caused by infection with a negative-strand RNA virus, Borna disease virus (BDV) (6, 8, 13, 14, 24) . The natural host range of BDV includes birds, cats, sheep, and horses (25, 26, 27) . Although the virus has not been recovered from human subjects, antibodies reactive with BDV proteins have been found in patients with bipolar depression, schizophrenia, or AIDS-related encephalopathy (4, 5, 35) .
BDV has a unique tropism for specific brain regions. Viral nucleic acids and disease-specific proteins have been found in highest concentrations in the hippocampus and limbic circuits, prefrontal and cingulate cortices, and brainstem nuclei (10, 25, 40) . Three BDV-specific proteins of 38/40, 24, and 14.5 kDa have been identified in infected cells and tissues (25, 44) . cDNAs for the 38/40-kDa antigen (p40) (24, 30, 34) and the 24-kDa antigen (p23) (24, 45, 49) have been isolated, and complementary sequences to open reading frames (ORFs) for these proteins have been mapped to the 3' end of the viral genome (8, 13) . Using methods for isolation of the 14.5-kDa protein (36) , we have purified a glycoprotein from BDVinfected rat brain that is encoded by a 429-nucleotide (nt) ORF located 3' to ORF p23 on the viral antigenome. The protein is predicted to be 16.2 kDa; glycosylation results in a 1-to 2-kDa increase in molecular weight. This glycoprotein, gpl8, is the first glycoprotein to be identified in the BDV system. Lectin binding and endoglycosidase sensitivity assays suggest that gpl8 is an unusual N-linked glycoprotein.
MATERIALS AND METHODS
Infection of animals and cultured cells. Animals and cells were infected with BDV strain He/80 (20, 37) . Newborn Lewis rats were infected by intracranial injection with 1.5 x 104 focus-forming units of BDV. Three weeks after infection, animals were sacrificed and brains were removed for isolation of BDV particles (9) or gpl8. C6 cells and MDCK cells were persistently infected with BDV as described previously (11, 20) . Monolayers of rabbit fetal glial cells were acutely infected by adding BDV at 1.0 focus-forming unit per cell to the culture medium (Dulbecco modified Eagle medium, 5% fetal calf serum; Gibco BRL).
Protein purification and microsequencing. Protein was purified from infected cells and tissues by detergent-salt extraction by the method of Schadler et al. (36) . For microsequencing, protein was cleaved with 10% cyanogen bromide in 75% formic acid (Sigma). Peptide fragments were separated by reverse-phase high-performance liquid chromatography (RP-HPLC) on a Vydac C-18 column, using a trifluoroacetic acidacetonitrile gradient. Sequence determinations were performed by automated Edman degradation on a Hewlett-Packard model G1000A protein sequencer.
Antibodies. Antibodies to purified gpl8 were produced in 3-month-old BALB/c mice. Animals were injected subcutaneously with 5 plg of protein in Freund's complete adjuvant and boosted 3 weeks later with a subcutaneous injection of 3 ,ug of protein in Freund's incomplete adjuvant. For 6 weeks thereafter, at 2-week intervals, animals received intraperitoneal injections of 5 pug of protein in phosphate-buffered saline (PBS) with 5 ,ug of lipopolysaccharide (Salmonella typhimurium; Difco) (three injections). Blood was drawn every 2 weeks during weeks 7 through 28 for measurement of serum antibody titer to purified protein by Western blotting (immunoblotting). Antisera collected at week 28 were used for virus neutralization studies. Rabbit antisera to recombinant BDV p40 and p23 were used as controls (7) .
Cloning and sequencing of cDNA encoding gpl8. gpl8-specific oligonucleotides were used to amplify full-length coding sequence for gp18 from two BDV-infected adult rat brain cDNA libraries (24, 30) as well as total cellular RNA (12) and poly(A)+ RNA (2) extracted from infected rat brain. Reverse transcription (RT) was performed with an oligo(dT) primer and Superscript II (Gibco BRL, Life Technologies, Inc.). PCR was carried out with Ampli-Taq Stoffel fragment according to standard protocols (Perkin-Elmer) with the following primer pair: 5'-terminal XhoI-gpl8 sense oligonucleotide (XhoI-gpl8-S1), TCCTCGAGATGAATTCAAAACATTCCTATG (nt 1892 to 1914; XhoI restriction site indicated by underlining); and 3'-terminal gpl8 antisense oligonucleotide (gpl8-AS1), CTAAGGCCCTGAAGATCGAAT (nt 2301 to 2321). Products were purified by agarose gel electrophoresis using a USBioclean purification kit (U.S. Biochemical) and cloned into Bluescript SKII+ (Stratagene) prepared with 3' T overhangs (28) . A minimum of three independent clones from each template source was sequenced on both strands by the dideoxynucleotide chain termination method using bacteriophage T7 DNA polymerase (Sequenase; U.S. Biochemical).
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The plasmid resulting from amplification of neonatally infected rat brain RNA was named pBDV-gpl8.
In vitro transcription, translation, and cotranslational processing. Plasmid clones pBDV-gpl8 and pBDV-23 (43) (24) .
Protein gel electrophoresis and immunoblotting. Proteins were size fractionated by SDS-PAGE (12% gel) and then transferred to Immobilon-N membranes (Millipore Corp.) (46) . Primary antisera for immunoblotting were from rats chronically infected with BDV (day 100 after intracranial infection) or mice immunized with purified gpl8. The secondary antibody was alkaline phosphatase-conjugated goat antimouse immunoglobulin G (Sigma); the substrate was Western Blue (Promega Corp.).
Carbohydrate analysis. Purified protein was size fractionated by SDS-PAGE (13% gel) and then either silver stained for detection of protein (18) or carbohydrate (48) (Fig. 1) .
Genomic sequence corresponding to the gpl8 ORF was used to design probes and primers for identifying mRNA encoding gpl8. In each of two cDNA libraries prepared from BDV-infected adult rat brain poly(A)+ RNA (24, 30) , 100,000 recombinants were screened by hybridization with a 271-bp HincII-Hinfl restriction fragment from pTB-BDV 5.82 (nt 2062 to 2333 in the viral genome) (8) . These libraries were also screened by PCR using the 5'-terminalXhol-gpl8 sense primer (nt 1892 to 1914) and oligo(dT). Total cellular and poly(A)+ RNAs extracted from persistently infected C6 cells, BDVinfected adult rat brain, or 3-week-old neonatally infected rat brain (the peak time point for in vivo expression of gpl8) were subjected to RT-PCR using oligo(dT) in combination with the 5'-terminal XhoI-gpl8 sense primer. No gpl8-specific transcript corresponding to the size of ORF gpl8 was obtained in these experiments. In contrast, use of the 5'-terminal XhoIgpl8 sense primer in combination with a 3'-terminal gpl8 antisense primer (nt 2301 to 2321) allowed amplification of gpl8 sequences from any of these sources by RT-PCR. In spite of variability at the nucleic acid level, the predicted amino acid sequence obtained from the different sources was the same as for strain V genomic sequence, with the exception of a single exchange in position 108 (E->D) (Fig. 1) .
Characterization of gpl8 as a glycoprotein. Purified gpl8 was size fractionated by SDS-PAGE. Modified silver staining revealed the presence of carbohydrate; thus, fractionated protein was blotted onto Immobilon-N membranes to determine the presence of individual saccharides through lectin binding studies. Binding was observed with Cancanavalia ensiformis agglutinin (ConA), wheat germ agglutinin, Datura stramonium agglutinin, BS-I, and BS-II but not with Galanthus nivalis agglutinin, Sambucus nigra agglutinin, Maackia amurensis agglutinin, and peanut agglutinin (Fig. 2) . This staining pattern was consistent with the presence of N-acetylglucosamine, N-acetylgalactosamine, mannose, and galactose. In addition, native and denatured proteins were digested with specific endoglycosidases, size fractionated by SDS-PAGE, and then stained to assess molecular weight shift and presence or absence of carbohydrate. Treatment with O-glycosidase or endoglycosidase H had no effect (data not shown). In contrast, treatment with endoglycosidase F and N-glycosidase F resulted in a loss of 1 to 2 kDa (Fig. 3) and abrogation of lectin staining with ConA (data not shown). Treatment with endoglycosidase F (N-glycosidase free) or endo-,B-galactosidase also resulted in a loss of 1 to 2 kDa (Fig. 3) .
In vitro transcription, translation, and processing of gpl8. With linearized pBDV-gpl8 used as a template, gpl8 RNA was transcribed and translated in vitro in either the presence or absence of canine microsomal membranes. The gpl8 RNA directed translation of two proteins of 16 and 18 kDa that were recognized by monospecific murine antiserum to purified gpl8.
Translation in the presence of microsomal membranes led to an increase in the relative proportion of the 18-kDa protein.
Treatment with endoglycosidase F resulted in loss of the 18-kDa protein species (Fig. 4A) . Glycosylation of the 18-kDa species was also shown by lectin binding studies performed after translation products were size fractionated by SDS-PAGE and transferred to membranes. The 18-kDa protein was recognized by ConA, whereas the 16-kDa protein did not bind 
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---+... ConA (Fig. 4B) . Modification of translated protein by the microsomal membranes was specific for gpl8. Translation of RNA encoding BDV p23, which encodes a potential Nglycosylation site (amino acids 53 to 55), included as a negative control for in vitro glycosylation, was not influenced by the presence of microsomal membranes (Fig. 4A) classical sites for N linkage (N-x-S/T [29] ) are found in the gpl8 sequence, the protein is readily modified in vitro in the presence of a microsomal membrane system capable of N glycosylation (16, 22) . In addition, gpl8 is sensitive to Nglycosidase F, an enzyme which cleaves between asparagine and N-acetylglucosamine (33, 41) . These findings indicate that gpl8 is N glycosylated at a nonclassical site. One potential site is N-I-Y (amino acids 74 to 76). The presence of a hydroxyl amino acid (T or S) or cysteine in position +2
(N-x-T/S or C) has been proposed as essential for hydrogen bond donor function in N glycosylation (3). It is possible that tyrosine (Y), another hydroxyl amino acid in position +2, could serve as a hydrogen bond donor in gpl8. A second potential site for N glycosylation is L-N-S-L-S (amino acids 87 to 91), which is similar to S-N-S-G-phosphorylated S, the site for N glycosylation in a glycopeptide from hen yolk phosvitin (39) .
gpl8 is sensitive to endoglycosidase F, an enzyme that cleaves after the N-linked N-acetylglucosamine in high mannose-, biantennary hybrid-, and biantennary complex-type oligosaccharides (41, 42) . The protein is not sensitive to endoglycosidase H, an enzyme which cleaves after the N-linked N-acetylglucosamine in high-mannose-and most hybrid-type oligosaccharides but does not cleave complex-type oligosaccharides (47) . Lectin (38) . The presence of galactose was confirmed by BS-I lectin binding (Fig. 2) . The presence of both N-acetylglucosamine and galactose was confirmed by high-performance anion-exchange chromatography with pulsed amperometric detection (data not shown). The combination of N-acetylgalactosamine and galactose is usually found in 0-linked carbohydrates (19) . Though it is possible that gpl8 is both N and 0 glycosylated, N-acetylgalactosamine has also been reported to occur in complex-type N-linked glycosylation (19 
